Health
The FDA declined to approve one of biotech’s most closely watched cancer drugs
Headline as filed by MarketWatch.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| MarketWatch | The FDA declined to approve one of biotech’s most closely watched cancer drugs |
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer. |
0m | marketwatch.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.